-

KalVista Pharmaceuticals to Provide Operational Update and Fiscal Quarter Financial Results on September 11, 2025

CAMBRIDGE, Mass. & SALISBURY, England--(BUSINESS WIRE)--KalVista Pharmaceuticals, Inc. (Nasdaq: KALV), today announced that the company will host a live webcast at 8:30 a.m. ET on Thursday, September 11, 2025 to provide an operational update and release financial results for the fiscal quarter ended July 31, 2025.

The webcast can be accessed on the Investors section of the Company’s website at Kalvista.com. A replay will be available for at least 30 days following the event.

About KalVista Pharmaceuticals, Inc.

KalVista Pharmaceuticals, Inc., is a global biopharmaceutical company dedicated to developing and delivering life-changing oral therapies for individuals affected by rare diseases with significant unmet needs. In the U.S., KalVista markets EKTERLY®, the first and only oral on-demand treatment for hereditary angioedema (HAE). The Company has multiple regulatory applications under review in key global markets. For more information about KalVista, please visit www.kalvista.com and follow us on LinkedIn, X, Facebook and Instagram.

Contacts

Investors:
Ryan Baker
Head, Investor Relations
(617) 771-5001
ryan.baker@kalvista.com

Media:
Molly Cameron
Director, Corporate Communications
(857) 356-0164
molly.cameron@kalvista.com

Industry:

KalVista Pharmaceuticals, Inc.

NASDAQ:KALV
Release Versions
English

Contacts

Investors:
Ryan Baker
Head, Investor Relations
(617) 771-5001
ryan.baker@kalvista.com

Media:
Molly Cameron
Director, Corporate Communications
(857) 356-0164
molly.cameron@kalvista.com

More News From KalVista Pharmaceuticals, Inc.

KalVista Pharmaceuticals Announces European Commission and Swissmedic Approval of EKTERLY® (sebetralstat), First and Only Oral On-Demand Treatment for Hereditary Angioedema

FRAMINGHAM, Mass. & SALISBURY, England--(BUSINESS WIRE)--KalVista Pharmaceuticals, Inc. (Nasdaq: KALV) today announced that the European Commission (EC) and Swiss Agency for Therapeutic Products, Swissmedic, have approved EKTERLY® (sebetralstat), a novel, oral plasma kallikrein inhibitor, for the symptomatic treatment of acute attacks of hereditary angioedema (HAE) in adults and adolescents aged 12 years and older. EKTERLY is the first and only oral on-demand treatment for HAE in the European U...

KalVista Pharmaceuticals Provides Operational Update and Reports Fiscal Quarter Financial Results

FRAMINGHAM, Mass. & SALISBURY, England--(BUSINESS WIRE)--KalVista Pharmaceuticals, Inc. (Nasdaq: KALV), today provided an operational update and released financial results for the fiscal quarter ended July 31, 2025. “This quarter marked a defining moment in the history of KalVista with the FDA approval of EKTERLY—the first and only oral on-demand treatment for HAE,” stated Ben Palleiko, CEO of KalVista. “Approval and launch on the same day propelled us immediately into our next chapter of growt...

KalVista Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

CAMBRIDGE, Mass. & SALISBURY, England--(BUSINESS WIRE)--KalVista Pharmaceuticals, Inc. (Nasdaq: KALV), today announced that the compensation committee of KalVista’s board of directors granted two newly-hired employees inducement options to purchase an aggregate of 5,000 shares of KalVista common stock on September 1, 2025 as inducements material to each employee entering into employment with KalVista. The options have an exercise price that is equal to the closing price of KalVista common stock...
Back to Newsroom